Friday, April 16, 2021 11:59:14 PM
Relief Therapeutics are not lazy Europeans. But they wont be fooled, if others try to buy their patent piece by piece. The cooperation with AdVita is now so successful that they care about the result of the clinical evaluation of their new study only and it doesn't matter whether NeuroRx is successful in case of EUA or not.
Relief originally funded the NeuroRx costs, but now it's game over. It is now up to Big Rock Partners whether they continue to show interest in Zyesami.
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM